MedDataX Logo

Development and Application of Patient-Derived Models of Cancer

NCT ID: NCT07226180

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-10

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to evaluate the clinical utility of investigational patient-derived cancer models, to assess the performance of biomarker-based therapeutic predictions in the patient-derived models.

Each participant in the observational study will have a piece of cancer removed as part of routine, physician direct care and grown in laboratory mice, where multiple anti-cancer drugs can be tested on it simultaneously. Additional data will be provided to the oncologist; interpretation of the results and any clinical actions are at the sole discretion of the oncologist.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants are planned to undergo a procedure, such as a biopsy or surgery, as part of routine care. After enough tissue to complete all routine tests required for the participants' care are provided, if the participant decides to take part in this study, any leftover biopsy or surgically obtained tissue/fluid, and blood specimens will be sent to the Certis laboratory for testing. It will be required to provide details regarding the participants' biopsy, such as the date, location, and contact information for the study team performing the procedure. The oncologist will assist with this, and once confirmed, a kit will be sent to the location of the procedure to transport the specimen back to the Certis laboratory in San Diego, California.

The process of developing an individualized PDX (Patient Derived Xenograft) model is a 2-step process. The first is Initiation, where the biopsy is surgically implanted into 2-5 specialized research mice, depending on the size and quality of biopsy received, to allow it to grow. This identifies if the participants' tumor is suitable for growing in mice, as well as generating enough tumor material to conduct large studies on. This takes approximately 3-4 months.

The next step is Pharmacology. Here, selected tumors from the initial 5 mice are removed, dissected, and implanted into a larger number of mice, approximately 50. These mice are then divided into groups of 5, and each group is given a different anti-cancer therapy. Certis will work closely with the oncologist to select the therapies to test. The mice are treated for a period of 4 weeks, and the tumors are measured weekly to determine which therapies are better at treating the participants tumor in mice. The oncologist will be updated upon pre-specified study milestones.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

solid tumor PDX patient-derived cancer models

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid tumor patients stage 2-4.
* Cancer patients who have been previously treated or shown resistance or refraction to standard-of-care therapies and where the implicated tissue has not been irradiated in the ten (10) weeks prior to excision.
* Patients with tumors are amenable to biopsy or surgery for fresh tissue and blood procurement as part of routine clinical care
* Patients must be referred by a healthcare professional
* Willingness for tissue samples used in future research
* Signed informed consent
* Willingness to share diagnosis, available genetic/molecular profiling data, treatment history, and treatment outcome monitoring

Exclusion Criteria

* Failure to provide informed consent
* Inaccessible tumors for biopsy or unavailability of tumor tissue for research purposes
* Subjects under the age of 18
* Subjects with cognitive impairment
* Pregnant subjects
* Contraindications to undergoing a biopsy procedure
* No prior treatments, naive
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Certis Oncology Solutions, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hoag Hospital Irvine

Irvine, California, United States

Site Status

Hoag Health Center Newport Beach

Newport Beach, California, United States

Site Status

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COS-IRB-001A - 220-23-CA

Identifier Type: -

Identifier Source: org_study_id